Decoding Low-Density Neutrophils in Breast and Lung Cancer: From Bystanders to Drivers

Clicks: 17
ID: 330058
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #52 of 100 articles by views in journal of leukocyte biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Neutrophils, once viewed as short-lived and functionally uniform antimicrobial cells, are now recognized as highly plastic immune regulators with context-dependent roles in cancer. Among circulating neutrophil subsets, low-density neutrophils (LDNs) have emerged as a clinically relevant population in oncology due to their distinct phenotypic, potent immunosuppressive activity, and strong association with disease progression. LDNs are rare in healthy individuals but markedly expanded in patients with solid tumors. LDNs display enhanced activation, increased expression of immunoregulatory molecules such as programmed death-ligand 1, elevated reactive oxygen species production, and a heightened propensity for neutrophil extracellular trap formation, collectively impairing cytotoxic T cell function and promoting tumor immune evasion. Although LDNs have been described across multiple malignancies, their biological and clinical relevance has been most characterized in breast and lung cancers. This review synthesizes current knowledge on neutrophil biology, emphasizing the clinical and mechanistic features of LDNs, with a focus on these two tumor types. In breast cancer, increased LDNs abundance correlates with metastatic disease, poor response to neoadjuvant chemotherapy, immunosuppression, accelerated progression, and reduced survival. In lung cancer, elevated LDNs frequencies similarly associate with advanced disease stage, unfavorable clinical outcomes, and distinct surface marker profiles distinguishing them from high-density neutrophils. Mechanistic studies indicate that tumor-derived cytokines and chronic inflammation drive LDNs expansion, functional reprogramming, and tissue trafficking, linking systemic neutrophil dysregulation to advanced disease and metastatic progression. Finally, we highlight emerging biomarkers, unresolved challenges, and therapeutic strategies targeting neutrophil plasticity and LDN-mediated immunosuppression, underscoring their potential as actionable components in precision oncology.
Reference Key
openalex_W7134928934 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Telma Martins, Rute M. Salvador, B.F.C. Correia, D.S.C.P. Grosa, Marina Vitorino, Inês Marques Sousa, Ana Rita Freitas, Cristiana Francisco, Marta Vaz Batista, Sofia Braga, António Jacinto, Maria Guadalupe Cabral
Journal journal of leukocyte biology
Year 2026
DOI
10.1093/jleuko/qiag126
URL
https://doi.org/10.1093/jleuko/qiag126
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.